Furthermore, in addition to eliminating activated HSCs, enhancing M2-polarized macrophage infiltration and CD8+ T cell activation due to TNC degradation through the use of CAR technology has been validated for the treatment of liver fibrosis. The gene discussed is CD8A; the disease is Hepatic fibrosis.